Close

Acorda Therapeutics, Inc. (ACOR) Misses Q3 EPS Views; Reaffirms Outlook

November 4, 2011 6:14 AM EDT
Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported Q3 EPS of $0.40, $0.33 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $93.03 million versus the consensus estimate of $90.78 million.

Acorda reiterates its 2011 net sales guidance.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance